Orphan Europe is a pharmaceutical company developing and distributing orphan drugs for the treatment of rare diseases. Whether you are a physician seeking help and support in your fight to treat a rare disease, a patient looking for information or a company looking for a partnership – Orphan Europe is waiting to hear from you.
 

On the top

Carbaglu®, an Orphan Europe Product Receives the "Pilule d'Or".

The 28/01/2008 at 16:14:34

The prestigious French review Prescrire rewarded the most important medicines in 2007 and awarded the “Pilule d’Or” (the golden pill), its highest distinction, to Carbaglu® (carglumic acid), an Orphan Europe product.


Read the news >>

Meet Orphan Europe at the The 5th International Cystinosis Conference

The 12/02/2008 at 11:17:40

It will take place in Dublin, Ireland on 27th and 28th June, 2008.


Read the news >>
 
 

Highlight

Orphan Europe Filed Carbaglu NDA with the FDA in the U.S.

The 21/04/2008 at 12:11:17

Recordati announced the submission to the U.S. FDA by Orphan Europe (a Recordati group company) of an Original New Drug Application (NDA) for Carbaglu® (carglumic acid). The NDA provides for the safe and effective use of Carbaglu® in the treatment of hyperammonaemia due to an autosomal genetic disorder resulting in the deficiency of the liver enzyme N-acetylglutamate synthase (NAGS deficiency).


Read the news >>
 

Orphan Europe provides treatment for patients suffering from rare diseases all over the world. Read more about the different diseases here.
Orphan Europe has been developing and distribution orphan drugs since 1990 and has today an extensive product portfolio. Read more about some of the orphan medicinal products provided by Orphan Europe.
Provides high-quality, innovative science education for healthcare personnel involved in the diagnosis and management of patients affected by rare diseases.
© Orphan Europe 2007 | Legal Information | Tools | | Send a friend | Design by Cyim 2007